Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Boehringer Ingelheim
Fuji
Farmers Insurance
Medtronic
AstraZeneca
Deloitte
Mallinckrodt
Accenture

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,423,722

« Back to Dashboard

Which drugs does patent 6,423,722 protect, and when does it expire?

Patent 6,423,722 protects ELIDEL and is included in one NDA.

Protection for ELIDEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty patent family members in thirty-two countries.
Summary for Patent: 6,423,722
Title: Crystalline macrolides and process for their preparation
Abstract:33-Epichloro-33-desoxyascomycin of formula I ##STR1## and various tautomeric or forms thereof, in crystalline form, such as Form A and Form B. Their preparation involves appropriately converting amorphous compound of formula I, or compound of formula I in other than Form A, or compound of formula I in other than Form B, respectively, from a solution thereof under crystallization-inducing conditions or conditions inducing preferential crystallization of Form A or B, respectively. Such crystals are particularly indicated for use in the preparation of topical galenical forms of the compound for pharmaceutical use, e.g. creams, emulsions and ointments.
Inventor(s): Dosenbach; Cornelia (Efringen-Kirchen, DE), Grassberger; Maximilian (Vienna, AT), Hartmann; Otto (Basel, CH), Horvath; Amarylla (Vienna, AT), Mutz; Jean-Paul (Blotzheim, FR), Penn; Gerhard (Oberwil, CH), Pfeffer; Sabine (Weil, DE), Wieckhusen; Dierk (Binzen, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:09/690,404
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 6,423,722

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Bermuda ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,423,722

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9713730Jun 30, 1997

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Accenture
Daiichi Sankyo
Federal Trade Commission
UBS
McKesson
US Department of Justice
US Army
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.